| DC12117 |
Luteolin 7-O-glucuronide (Luteolin 7-glucuronide4)
Featured
|
Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively. |
|
| DC7456 |
LX1606 Hippurate
Featured
|
LX1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity. |
|
| DC10754 |
LX2343
Featured
|
LX-2343 is a novel non-ATP competitive PI3K inhibitor, negatively regulating AKT/mTOR signaling, thus promoting autophagy, and increasing A-beta clearance. |
|
| DC7921 |
Sotagliflozin (LX-4211)
Featured
|
LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents. |
|
| DC10828 |
LXH254
Featured
|
LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor. |
|
| DC2072 |
LXR623
Featured
|
LXR-623 is a novel Liver X Receptor modulator |
|
| DC26012 |
LXS-196
Featured
|
LXS196 is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. It can be used for the treatment of uveal melanoma. |
|
| DC8602 |
LY311727
Featured
|
LY 311727 is a specific group II sPLA2 (phospholipase A2 (PLA2)) inhibitor which has been reported to attenuate VEGF-mediated platelet-activating factor (PAF) synthesis in HUVEC and BAEC cells. |
|
| DC7944 |
LY2090314
Featured
|
LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50s of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β respectively. |
|
| DC8435 |
LY2119620
Featured
|
LY2119620 is a specific, and allosteric agonist of human M2 and M4 muscarinic acetylcholine receptors. |
|
| DC6306 |
LY2157299(Galunisertib)
Featured
|
LY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM. Phase 2. |
|
| DC8630 |
Ralimetinib 2MsOH(LY2228820)
Featured
|
LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38αMAPK and p38βMAPK were 7 nM and 3 nM, respectively). |
|
| DC9304 |
LY2334737
Featured
|
LY2334737 is an orally available prodrug of gemcitabine which is a nucleoside analog used as chemotherapy. |
|
| DC9975 |
Ly 2365109 Hydrochloride;n-[2-[4-(1,3-benzodioxol-5-yl)-2-(1,1-dimethylethyl)phenoxy]ethyl]-n-methylglycinehydrochloride
Featured
|
LY2365109 is a potent and selective GlyT1 inhibitors with IC50 value of 15.8 nM. |
|
| DC8065 |
LY2409881 trihydrochloride
Featured
|
LY2409881 is a novel inhibitor of IκB kinase β (IKK2). |
|
| DC23720 |
LY2452473
Featured
|
LY2452473 is an orally bioavailable, selective androgen receptor modulator (SARM). |
|
| DC10782 |
LY2510924
Featured
|
LY2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. |
|
| DC24072 |
LY-2584702 free base
Featured
|
LY2584702 is a potent, selective, ATP-competitive inhibitor of P70 S6 kinase-1 (p70S6K1) with IC50 of 4 nM. |
|
| DC24073 |
LY-2584702 hydrochloride
Featured
|
LY2584702 is a potent, selective, ATP-competitive inhibitor of P70S6 kinase-1 (p70S6K1) with IC50 of 4 nM. |
|
| DC7943 |
LYS6K2(LY2584702) tosylate salt
Featured
|
LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes. |
|
| DC7103 |
LY2603618(IC-83)
Featured
|
LY2603618(IC-83) is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to enter clinical cancer trials. |
|
| DC7993 |
Prexasertib (LY2606368) 2HCl
Featured
|
LY2606368 2Hcl is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. |
|
| DC10796 |
Prexasertib (LY2606368)
Featured
|
LY2606368 is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. |
|
| DC7458 |
LY2608204
Featured
|
LY2608204 is a activator of glucokinase (GK) with EC50 of 42 nM. |
|
| DC7665 |
Gandotinib(LY2784544)
Featured
|
LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2. |
|
| DC23510 |
LY2794193
Featured
|
LY2794193 is a highly potent and selective mGlu3 receptor agonist with Ki of 0.93 nM and EC50 of 47 nM, >100-fold selectivity over mGlu2 receptor.. |
|
| DC10815 |
LY2795050
Featured
|
LY2795050 is a novel selective κ-opioid Receptor (KOR) antagonist (IC50=0.72 nM) and has the potential as a PET tracer to image KOR in vivo. |
|
| DC7035 |
Merestinib(LY2801653 dihydrochloride)
Featured
|
LY2801653 2HCl is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM). |
|
| DC8586 |
LY2801653
Featured
|
LY2801653 is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM). |
|
| DC5180 |
LY2811376
Featured
|
LY2811376 is the first orally available non-peptidicβ-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM. |
|
